Antisense compositions and methods for modulating type I interleukin-1 receptor expression
US5856099A · kind A · utility
7Cited by
15References
29Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 21, 1996 |
| Grant date | Jan 5, 1999 |
| Priority date | — |
| Expiry date | May 21, 2016 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/322
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions and methods are provided for the treatment and diagnosis of diseases amenable to treatment through modulation of type I IL-1 receptor mRNA expression. In accordance with preferred embodiments, oligomers are provided which are specifically hybridizable with DNA or RNA encoding type I interleukin-1 receptor. Methods of modulating type I IL-1 receptor expression and of treating animals suffering from diseases amenable to therapeutic intervention by modulating the expression of type I interleukin-1 receptor with an oligomer specifically hybridizable with DNA or RNA encoding type I interleukin-1 receptor are disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.